RxDoctor Payments Data

Marcia Peck, MD

Endocrinology, Diabetes & Metabolism · Castro Valley, CANPI 1376569475

Payments from drug & device makers

$1,787in general payments, 2019–2025

Across 30 payments — averaging $59.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$450
  • Amgen$407
  • Dexcom, Inc.$298
  • Sanofi-aventis U.S. LLC$184
  • AstraZeneca$119
  • Ascendis Pharma Endocrinology Inc$114
  • plus $215 from 4 others

What the payments were for

  • Consulting fees$62535%
  • Speaking & faculty fees$22913%
  • Food & beverage$84547%
  • Education$885%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,787 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$331,380
Medicare patients
363
Services billed
6,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide215$357,897
JardianceEmpagliflozin191$290,107
TrulicityDulaglutide95$157,863
JanuviaSitagliptin Phosphate71$98,487
MounjaroTirzepatide72$95,247
ForteoTeriparatide13$59,400
RybelsusSemaglutide25$50,638
Tresiba Flextouch U-100Insulin Degludec52$35,425
Fiasp FlextouchInsulin Aspart (Niacinamide)25$32,526
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$25,285
Lyumjev Kwikpen U-100Insulin Lispro-Aabc35$24,414
TradjentaLinagliptin19$24,361
Tresiba Flextouch U-200Insulin Degludec17$24,019
Repatha SureclickEvolocumab18$23,631
Victoza 3-PakLiraglutide16$23,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog$19$322,374212 claims
AstraZenecaFarxiga$119$14,07413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Castro Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →